	US 12,405,267 B2
	Diagnosis, prognosis and treatment of a disease related to a decrease of F. prausnitzii
Frédéric Altare, Nantes (FR); Guillaume Sarrabayrouse, Barcelona (ES); Harry Sokol, Paris (FR); Emmanuelle Godefroy, Nantes (FR); and Francine Jotereau, Nantes (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); UNIVERSITE D'ANGERS, Angers (FR); UNIVERSITE DE NANTES, Nantes (FR); ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR); and SORBONNE UNIVERSITÉ, Paris (FR)
Appl. No. 17/059,315
Filed by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); UNIVERSITE D'ANGERS, Angers (FR); UNIVERSITE DE NANTES, Nantes (FR); ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR); and SORBONNE UNIVERSITE, Paris (FR)
PCT Filed May 31, 2019, PCT No. PCT/EP2019/064210 § 371(c)(1), (2) Date Nov. 27, 2020, PCT Pub. No. WO2019/229247, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 18305677 (EP), filed on Jun. 1, 2018.
Prior Publication US 2021/0215676 A1, Jul. 15, 2021
Int. Cl. G01N 33/50 (2006.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/40 (2025.01); A61K 40/41 (2025.01); A61K 40/45 (2025.01); G01N 33/569 (2006.01)

CPC G01N 33/5091 (2013.01) [A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/40 (2025.01); A61K 40/416 (2025.01); A61K 40/45 (2025.01); G01N 33/505 (2013.01); G01N 33/56911 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01)]

3 Claims

1. A method of treating a subject afflicted with a disease characterized by a decrease of F. prausnitzii, wherein said method comprises:

a) determining the number and/or concentration and/or proportion of T lymphocytes with a CD4⁺ CD8αα^lowCCR6⁺ phenotype, a CD4⁺ CD8αα^lowCXCR6⁺ phenotype and/or a CD4⁺ CD8αα^lowCCR6⁺ CXCR6⁺ phenotype, in a biological sample from the subject, optionally, comparing the result of step a) with i) a control standard value corresponding to the number and/or concentration and/or proportion of these T lymphocytes typically found in a biological sample of the same nature from a healthy subject, and/or ii) a control standard value corresponding to the number and/or concentration and/or proportion of these T lymphocytes typically found in a biological sample of the same nature from a patient suffering from said disease characterized by a decrease of F. prausnitzii;

b) deducting from the result(s) of step a) and/or step b) where appropriate, if the subject is afflicted with a disease characterized by a decrease of F. prausnitzii, and

c) administering a suitable treatment to the subject deduced in step c) to be afflicted with a disease characterized by a decrease of F. prausnitzii, wherein said suitable treatment is selected from the group consisting of an immunosuppressant, a probiotic, an antibiotic, F. prausnitzii, a fragment of F. prausnitzii, a pharmaceutical composition comprising isolated T lymphocytes with a CD4⁺ CD8αα^lowCCR6⁺ phenotype, a CD4⁺ CD8αα^lowCXCR6⁺ phenotype and/or a CD4⁺ CD8αα^lowCCR6⁺ CXCR6⁺ phenotype and their combinations.